ArticleFrontiers in public health2025

Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China.

Huiyuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.